Bridgeway Capital Management, LLC Applied Genetic Technologies Corp Transaction History

Bridgeway Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.62 - $1.1 $9,005 - $15,977	-14,525 Reduced 8.55%	155,375 $120,000
Q4 2021 Feb 14, 2022	SELL	$1.87 - $2.91 $48,620 - $75,660	-26,000 Reduced 13.27%	169,900 $323,000
Q2 2021 Aug 16, 2021	BUY	$3.62 - $5.23 $289,600 - $418,400	80,000 Added 69.03%	195,900 $766,000
Q2 2020 Aug 14, 2020	BUY	$3.0 - $6.9 $105,000 - $241,500	35,000 Added 43.26%	115,900 $642,000
Q1 2020 May 15, 2020	SELL	$2.36 - $9.86 $52,864 - $220,864	-22,400 Reduced 21.68%	80,900 $265,000
Q2 2019 Aug 14, 2019	BUY	$3.6 - $4.78 $72,000 - $95,600	20,000 Added 24.01%	103,300 $392,000
Q1 2019 May 15, 2019	SELL	$2.62 - $4.44 $113,708 - $192,696	-43,400 Reduced 34.25%	83,300 $349,000
Q3 2018 Nov 13, 2018	SELL	$3.85 - $7.35 $96,250 - $183,750	-25,000 Reduced 16.48%	126,700 $925,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.65 $203,500 - $310,750	55,000 Added 56.88%	151,700 $561,000
Q1 2018 May 15, 2018	BUY	$3.65 - $5.2 $15,695 - $22,360	4,300 Added 4.65%	96,700 $372,000
Q3 2017 Nov 14, 2017	BUY	$3.55 - $5.25 $328,020 - $485,100	92,400	92,400 $365,000

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.